Gene explains breast cancer chemotherapy outcomes
WASHINGTON (Reuters) – Genetic mutations can show which breast cancer patients will be helped by a certain type of chemotherapy, U.S. researchers reported on Tuesday.
They found patients with two versions of the SOD2 fared worse when taking the chemotherapy drug cyclophosphamide than other patients. It might be useful to test patients for this gene before giving them the drug, the researchers reported in the journal Clinical Cancer Research.
"In the future, such tests may be used to guide the treatment of patients with the SOD2 variation, ensuring that they receive a therapy that is more effective than cyclophosphamide-based therapies," Dr. Stefan Ambs of the National Cancer Institute, who worked on the study, said in a statement.